Core Viewpoint - As of July 30, 2023, AAPG's stock price increased by 2.29% to $40.168 per share, with a total market capitalization of $3.734 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - The company has developed a proprietary drug design platform targeting protein-protein interactions and is at the forefront of new drug development in the apoptosis pathway. AAPG has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development [2]. - AAPG's core product, Orebatinib (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance Drug List. The product has also received various designations from the FDA, including Fast Track and Orphan Drug status [2]. Clinical Development and Collaborations - The company is conducting over 40 clinical trials across China, the United States, Australia, and Europe. It has four investigational new drugs that have received 16 FDA orphan drug designations, two FDA Fast Track designations, and two FDA designations for pediatric rare diseases [2]. - AAPG has undertaken several national science and technology major projects, including five under the "Major New Drug Creation" initiative. The company has established global collaborations with leading biotech and pharmaceutical companies and academic institutions [2].
亚盛医药上涨2.29%，报40.168美元/股，总市值37.34亿美元